ANEMOCYTE
LIVE

Serial Number

79211373

Owner

ANEMOCYTE S.R.L.

Attorney

Brian A. Tollefson

Filing Date

Feb 6, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ANEMOCYTE Trademark

Serial Number: 79211373 • Registration: 5440621

ANEMOCYTE is a trademark filed by ANEMOCYTE S.R.L. on February 6, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ANEMOCYTE S.R.L. (5 trademarks)

Via R. Lepetit, 34

Entity Type: 16

ARETA INTERNATIONAL S.R.L. (2 trademarks)

Via Roberto Lepetit, 34

Entity Type: 03

Trademark Details

Filing Date

February 6, 2017

Registration Date

April 10, 2018

Published for Opposition

January 23, 2018

Goods & Services

Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues ] for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues ] for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription ] medicines, namely, [ pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, ] vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes ] ; biological reagents for medical use; medicinal products based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical [ and veterinary ] purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; [ biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; ] [ products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; ] products for personalized medicine made of [ autologous cells or proteins or ] nucleid acids derived from individual genomic sequences; [ preparations made up of cells for medical or clinical use; ] preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]

Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes

Filing History

INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Feb 9, 2026 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 6, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Sep 16, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Sep 16, 2025 C75A
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Aug 22, 2025 EROP
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 16, 2025 INPR
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Jun 6, 2025 PR75
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 15, 2025 EROP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 15, 2025 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
May 15, 2025 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 15, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 15, 2025 REAP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Dec 16, 2024 PR75
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 20, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Apr 9, 2024 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 10, 2023 REM3
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 24, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 24, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 24, 2022 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 24, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 24, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 24, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 24, 2022 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 11, 2018 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Jul 16, 2018 FICS
FINAL DISPOSITION PROCESSED
Jul 16, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 10, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 10, 2018 R.PR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 22, 2018 ADCH
NOTIFICATION PROCESSED BY IB
Feb 10, 2018 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 23, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jan 23, 2018 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 3, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 3, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 11, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 11, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 20, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 20, 2017 REAP
REFUSAL PROCESSED BY IB
Aug 4, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 18, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jul 18, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 12, 2017 RFCR
APPLICATION FILING RECEIPT MAILED
Jul 12, 2017 MAFR
NON-FINAL ACTION WRITTEN
Jul 11, 2017 CNRT
ASSIGNED TO EXAMINER
Jul 8, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 7, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 6, 2017 REPR